Bio Job Blog : Bio Jobs : Biotechnology Jobs : Biopharmaceutical Jobs : Bioscience, Biotech Jobs : Bio Job Blog : Biocareer : Bio-Business Training, Biotechnology Training : Jobs in Biology : Internships in Biology : Internships in Biotechnology

BioCrowd, a new social networking site for bioprofessionals was officially launched today.  We are still making last minute fixes and cosmetic changes so please bear with us over the next few weeks.

BioCrowd's main goal is to provide a venue for career development and business interactions for students, scientists and other bioprofessionals.  We plan on adding new applications and functionality as the network evolves.  That said, please let us know what you think, what you like and don't like and how we can improve BioCrowd to meet your needs.

Thanks and I hope that you become a member of the BioCrowd!

Until next time...

Good Luck and Good Job Hunting!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

For those of you virology junkies out there, This Week in Virology (TWiV) has just released a podcast on the top 10 virology stories of 2008. BioCrowd founder, Vincent Racaniello and Alan Dove, a professional science writer (and one of Vincent's former students), discuss their top picks for 2008 and make some predictions for 2009.

For those of you with no plans for this evening’s festivities, open a bottle of champagne, kick back and have a listen—it's good stuff!

Until next time…

Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The recent spate of corporate layoffs has forced many people to reconsider what their next career move ought to be. While looking for another corporate job (similar to your old one) is the most obvious thing to do, the likelihood of quickly finding a new job in these economic times is remote. That said, now may be a good time to consider leaving confines of the corporate world and striking out on your own! Based on my own personal experiences, this can be a very frightening and overwhelming undertaking fraught with anxiety and uncertainty. But, not to worry! Sharon Jaffe, a self described “passionate digital marketing and media strategist and former corporate executive” has written a great blog post that offer some helpful tips and suggestions  for people who may be thinking about leaving the comforts of the corporate world and striking out on their own.

Sharon’s Tips and Suggestions About Starting Out on Your Own

1. Feel the fear and do it anyway. This is a great book by Susan Jeffers, and it's my main point, since 96% of people don't start a new busineness because of the fear of failure.  Don't expect to be fearless, but don't be paralysed by your fears. Help and seek help, especially where you need it – be it logistics, network, introductions etc.

2. "Do unto others..."- The Ethic of Reciprocity. Don't underestimate your own value and your ability to help others. Realise that others want to see you succeed and need your help too, so jump in the "informal economy" of networking, connecting, giving and asking for help. I wouldn't be here today if it wasn't for key people who gave me their time and guidance. In turn, I always make time for others since you never know when the favour will be returned. ;-)

3. Network isn't everything, it's the only thing! It's what you know AND who you know. The people who've worked with you and know what and how you do it are the key people to hire you, help you and recommend you on. Almost all my business has come from my own network where I have spent many years building a reputation and building my personal brand.

4. Be resilient! Be prepared to bark up a lot of wrong trees. When there's nothing up the trees, pick yourself up and move on to the next one. Set-backs and disappointment are par for the course. Protect your self-esteem and be positive. Matt Crabtree, from Positive Momentum, was instrumental in helping me with most of these tips as well as recognising the power of the right attitude and positivity.

5. Be your own guiding light. Trust your internal instincts when making decisions and be true to yourself. If you're asked to do something which doesn't feel right or by someone who doesn't feel right, it generally isn't right. Don't accept work which you don't feel good about i.e. is not the type of work you want to be doing (you'll be hating every minute of it). At the same time, be open-minded. I was asked to do training and figured, "why not?". It has since turned out to be my main source of business second to consulting.

6. Quality is key! Maintain your own professional quality standards. Invest in your brand and pay attention to everything from the way you dress to showing up on time. Now more than ever it's important to realise that you are your own business card.

7. Have a clear vision. Always hold clear the vision of where you see yourself in 1 or x year's time. Let that motivate you! Make sure you create some goals and milestones, be it a revenue target, or your first press interview. Remember to also reward yourself and congratulate yourself on your achievements along the way with rewards.

8. Think big but start small. Don't be arrogant or overconfident in what you charge. Be willing to do stuff for free to build experience, reputation and a solid track record. Trust me, the rest will follow.

9. Watch your costs. Don't splurge unnecessarily but don't skimp on the important things like a good laptop and a business card. It's not necessary to have a glamorous website to get started – one year on I still don't advertise what I do on the web and yet I've been fully booked.

10. Manage your work-life balance. It's easy to start working evenings and weekends and it's hard to give yourself a break. I think this is a key driver of entrepreneurs and a danger in the general unwillingness or inability to take time off. I think I'm still learning this one, which is why I put it last.

I hope these tips are helpful! Good luck!

You can follow Sharon on Twitter @sharonjaffe

Until next time…

Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Like most graduate students, I diligently followed the advice of my thesis advisor and was lucky enough to land tenure track position at the University Of Miami School Of Medicine. While I was slogging my way toward that appointment, I began to experience some troubling and persistent concerns about my career as an academic. I really didn’t like doing bench research that much, I wasn’t a very good politician and I had a burning desire to teach. Unfortunately, I chose to listen to what others thought was in my best interests rather than listen to myself.

I spent my first two years at UM wondering why I had agreed to take the job—I had no grant money, no graduate students and no life. I was truly miserable. I didn’t realize it until many years later that I was experiencing a full-blown, career crisis a the tender age of 32. I suffered in silence because I was afraid that if I shared my feelings with my colleagues they would think that I was crazy. After all, “not everybody was able to win a tenure track appointment at an up and coming medical school like UM.” Not surprisingly, those two torturous years of indecision and confusion cost me tenure five years later. While being denied tenure was one of the most difficult and devastating experiences of my life, it was probably one of the best things that ever happened to me. It forced me to reconsider my career objectives and helped me to chart a career path that was more consistent with my personality, talents and skills.

I hadn’t thought much about my former life as an academic, until I came across an article in this Sunday’s NY Times entitled “In a Life of Firsts It’s the Seconds that Count Most.” It was written by David Rosen, an advertising executive who started having second thoughts about his job shortly after he started it. His story was surprisingly similar to mine, and like me, he ignored some of the early warning signs that his intended career may not have been the best career choice for him. He ultimately left advertising and is now quite satisfied with his career as a writer.

Like Mr. Rosen, I learned a few things that I think may be helpful to others who may be struggling with their next career move. First, there is no such thing as a “universal career road map”—one size doesn’t fit all. Second, there are no right or wrong career paths—only the one that you create for yourself. Finally and perhaps most importantly, always follow the advice of your heart—some sage advice from a fortune cookie that has always served me well!

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

• Email This
• Print
• Comments (2)
• Trackbacks
• Share Link

Glassdoor.com a site that allows people to rate CEO and company performance selected Arthur Levinson, one of the original founders and current CEO of Genentech as the “nicest CEO” of the year. Dr. Levinson received a 93 percent approval rating and he is the only biotech CEO on the list. A strategic planner at Genentech wrote “He leads the Silicon Valley biotech company with a “decision-making structure that intrinsically forces authority downward to the lowest possible level providing many opportunities to exercise and test one’s judgment.”  I have worked with Genentech on education and training initiatives in the past and as far as I am concerned it is “second to none” in the biotech industry. 

It is evident from Genentech’s continued success, that Dr. Levinson is truly one of the unsung heroes (and pioneers) of the biotechnology industry. I am glad that he is finally getting the recognition that he deserves.

Until next time…

Good Luck and Good Job Hunting (try Genentech, they are hiring!)

• Email This
• Print
• Comments
• Trackbacks
• Share Link

For those of us who grow up in the New York Metropolitan area, the WPIX Yule was a family Christmas tradition (even for Jewish kids like me). Every Christmas morning, we would get up, turn on the TV, surf over to WPIX and watch the yule log burn all day long. I think that back iin the day, the television station probably ran a video loop (rather than train a camera all day on the yule log) but it was as close as we could come to today's web cams (for reference purposes, IBM mainframes were de riguer at the time). Those were the days!!!!!

Unfortunately, the yule log disappeared for over 30 years until WPIX decided to resurrect it several years ago because of popular demand (there are a lot of baby boomers out there). While many of you don't receive the WPIX digital signal, it doesn't mean that you can't enjoy the Yule log experience. You can now view it on YouTube!

 Happy Holidays!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Do you ever wonder how popular twitter is or how many followers the average twitter has? Well wonder no more. You can find answers to these questions and more by reading ‘State of the Twittersphere (Hubspot Edition)’ that was recently posted on Tech Crunch.

I started tweeting in earnest about two months ago and I am convinced that Twitter and other microblogging platforms are the next generation of social media tools. So, move over LinkedIn, Facebook and My Space because the Twitterverse is expanding.

BTW, you can follow BioJobBlog on twitter @ BioJobBlog.

Until next time…

Good Luck and Good Tweeting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

For those of you who haven’t been able to keep up with the latest pharma layoffs, I came across an article in the Philadelphia Business Journal that does an excellent job of recapping all of the major life sciences layoffs that have taken place in the past year or so. The recent massive pharma layoffs prompted William Ashton, Acting Dean of the University of the Sciences in Philadelphia PA to say “I was in the pharmaceutical industry for 28 years. I’ve never seen such a sea change as is occurring right now. This is really dramatic.” Further, Dr. Ashton predicted that drug companies will increase their use of contract sales forces (CSFs) and contract research organizations (CROs) to contain expenses and that staffing firms will be the winners.

This led to me to wonder what Dean Ashton has been doing for the past 10 years or so because the life sciences industry has already increased its reliance on CROs and CSFs. A quick perusal of the pharma and biotech employees who lost their jobs over the past few years reveals that a majority of them were in sales and R&D. I don’t know whether or not I should break the news to Dean Ashton, but the future is already upon us—another example of how out of touch academia is with industry in the 21^st century.

I think that it is time for industry executives and academicians to begin a serious dialog to determine the type of training that would be appropriate for individuals seeking jobs in the life sciences industry. A failure to do so will likely have a negative adverse effect on the continued growth and future success of the US life science industry.

Until next time…

Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Like it or not, the best way to land a new job whether or not there is a recession is to network. While career counselors and recruiters trumpet the virtues of networking to job seekers, many people really don't understand what it is or how to do it correctly. I found an outstanding article that demystifies networking and offers tips on how to excel at it. 

For many scientists, online networking is ideal because they frequently lack the requisite skills to effectively network in real life situations. Until recently, face-to-face networking at conferences or "professional social events" was the only way to effectively network. However, the advent of web-based social networks allows job seekers to eschew the awkwardness and time requirements for  one-on-one networking in favor of a more convenient and less-threatening online experience. BioCrowd, a new online social network for scientists and other bioprofessionals, was created to help scientists advance their careers and find new jobs. While BioCrowd and similar online networking sites can help scientists make connections, it is still the face-to-face networking experience that will ultimately  help them land new jobs!

Because networking is not taught or emphasized in graduate school, it is not surprising that many graduate students and postdoctoral fellows are notoriously poor “networkers.” That said, for those of you who recognize the importance of networking and want hone your networking skills, Contacts Count a Maryland-based network training company may be worth a visit. I have no doubt that there other organizations and companies out there that specialize in network training. If you find any, let me know and I will gladly post them!

Until next time…

Good Luck and Good Job Hunting

• Email This
• Print
• Comments (2)
• Trackbacks
• Share Link

I had little to do last night, so I decided to download Stumble Upon for Firefox.  While I was stumbling, I came across an outstanding video that teaches and reinforces the underlying principles of chemical reactions. If I had this type of tutorial when I was an undergraduate, I might very well have become a chemist rather than a biologist!

Until next time….

Good Luck and Good Reactions!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Targanta Therapeutics, a Cambridge, MA-based biopharmaceutical company, announced that it will lay off 85 of its 115 employees or almost 75% of its workforce. The news follows the FDA’s rejection of its application for oritavancin, an antibiotic it is developing to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic resistant bacteria. The agency wants Targanta to conduct another Phase III clinical trial to further assess of oritavancin’s safety and efficacy.

The company estimates that the new clinical trial will cost about $20 million. Targanta CEO Mark Leuchtenberger said “We are no longer a pre-commercial company. We are back to being a Phase three company, and that requires us to right-size and to streamline our operations.”

Things are not going well for companies in the antibacterial drug discovery and development space. Late last month, FDA rejected Swiss-based Arpida’s NDA for iclaprim an antibiotic it was developing to treat complicated skin and soft infections caused by MRSA. Shortly after receiving the news, Arpida layed off roughly 72% of its employees and is down to about 30 employees like Targanta.

It is unfortunate that big pharma decided to abandon antibacterial discovery and development research about eight years ago. Consequently, development of  new, much-needed antibiotics has been relegated to financially-strapped, small biopharmaceutical companies whose likelihood of success is questionable.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Pfizer announced yesterday that it would invest $75 million upfront and possibly $410 million more to buy the European rights from Auxilium Pharmaceuticals to develop an experimental biologic (a clostridial collegenase) called Xiaflex to treat Peyronie’s Disease (PD). For those of you who have never heard of PD—I hadn’t— it is “a condition of uncertain cause is characterized by a plaque, or hard lump, that forms on the penis. The plaque develops on the upper or lower side of the penis in layers containing erectile tissue. It begins as a localized inflammation and can develop into a hardened scar.” The buildup of collagen on the shaft of the penis reduces flexibility and makes intercourse uncomfortable. Apparently, this condition can affect close to 1 percent of men according to the National Institutes of health. Prior to development of Xiaflex, treatments for PD ranged from oral Vitamin E therapy to corrective surgery.

I am sure that PD is very painful and causes a lot discomfort and anxiety for men who suffer from it. And there should be a treatment for it!  However, Viagra, another Pfizer product that was approved for erectile dysfunction (ED), has become more of a recreational drug than an ED treatment. I suspect that Xiaflex will not reach blockbuster status like Viagra because it requires penile injection for efficacy (Ouch!). That said, Pfizer may also develop Xiaflex to treat Dupuytren’s contracture and Frozen Shoulder syndrome, two other collagen-related diseases that afflict a significantly higher number of patients than PD. Nevertheless, from a marketing perspective, any drug that is developed to treat penile dysfunctions or problems is likely to be a BIG winner! Now, I understand what has been keeping Pfizer execs at night (sorry, but I couldn't  resist)!

Hat tip (so to speak) to Ed at Pharmalot!

Until next time…

Good Luck and Good Job Hunting

• Email This
• Print
• Comments
• Trackbacks
• Share Link

In a  previous post,  I suggested that more layoffs would occur at Bristol-Myers Squib (BMS) by December, 1, 2008. The Pharmalot Blog reported today that 800 more BMS employees ( including scientists) would lose their jobs before the end of 2008. Okay, so I was off by about two weeks.

A company spokesperson told the Pharmalot folks that “We are reducing the global Bristol-Myers Squibb workforce as part of our previously announced second wave of productivity initiatives designed to enhance our ability to address the significant challenges and uncertainties our company faces in the short- and long-term. Headcount reductions associated with the second wave of productivity initiatives will continue through 2010, with a goal of a 10 percent reduction in our global workforce. This [layoff of 800] is in addition to the 10 percent workforce reduction previously announced in December 2007.” 

Things are obviously not going well at BMS these days. Look for more layoffs in early 2009 and beyond. Who do you think is going to buy BMS?

Until next time…

Good Luck and Good Job Hunting (Try Lilly I hear ImClone is looking for a few good men and women)

• Email This
• Print
• Comments
• Trackbacks
• Share Link

I’ve blogged on this topic many times in the past. However, I came across a great blog post that summarizes at least five of mine into a concise, practical and resourceful guide to finding a new job.

Read it and keep on looking—there are still jobs out there for highly specialized individuals like scientists!

Until next time…

Good Luck and Good Job Hunting!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

For the past five years, I have been giving career development seminars that offer graduate students and postdoctoral fellows alternate careers choices (instead of research) for life scientists. The intent of these seminars is to get students who may not be enamored with a possible life long career at the bench (I know that there a lot of you out there) to think about what they really want to do after they complete their graduate or postdoctoral training.

I recently met Jane Chin (on Twitter) who, like me, has had an unorthodox career trajectory for a life scientist. After exchanging several tweets, I learned that we both are microbiologists, Cornell University graduates, entrepreneurs and social media enthusiasts. But, the main reason I am telling you about Jane is that she crafted a fascinating PowerPoint presentation entitled “3 Lessons About Career Life From a Career Nomad” that provides insights into the decisions and choices that she made to shape her current career path. I highly recommend that you take a peek at the presentation—it may help to reduce some future career stress and angst!

Until next time…

Good Luck and Good Job Hunting!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The relationship between science, education and industry has always been a tenuous one. To learn more about the complexity of this relationship check out this article that was recently published in a local New Jersey business publication.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Pfizer announced today that it will eliminate almost 1,000 jobs in France through layoffs or voluntary departures. Gerard Bouquet, vice-president of Pfizer France, announced that "This new organization will take effect from Dec. 1, 2009 and there will be no forced layoffs before that date.” The cuts will affect Pfizer’s sales force and at it Paris-based headquarters.

Today’s announcement comes just a few days after Rod MacKenzie, Pfizer’s worldwide head of discovery research told reporters “Given the complexity of the changes within research, I have concluded that we will not be able to provide that clarity [for the layoffs] or communicate them by the end of the year." While it appears that there may some confusion regarding American workers, this is clearly not the case for Pfizer’s European employees.

Until next time…

Good Luck and Good Job Hunting

• Email This
• Print
• Comments (2)
• Trackbacks
• Share Link

I received a phone call late Thursday afternoon from the general counsel from the Biotechnology Industry Organization (BIO).  At first I thought he was calling to invite me to give a talk at this year's annual meeting, but after he mentioned something about a blog post circa Feb. '08, I quickly realized that it wasn't going to be a fun call.  It turns out that I inadvertently and mistakenly uploaded  BIO's logo to the post. Because I was not authorized to use the logo, I had violated BIO trademarking rights.  After I hung up, I quickly removed the logo.  And, I am happy to report that the post is alive and well (albeit photo-less).

What strikes me as curious is that the post in question had been on the blog for almost a year. Interestingly, the call asking me to remove the logo came about 24 hours after posting a piece that was unkind to a proposed biotechnology industry bailout package. I think the call was BIO's way of telling me that from this day forward they will be carefully monitoring BioJobBlog.   So it goes....the more the merrier!

Until next time....

Good Luck and Good Job Hunting!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Over the past few weeks, the blogosphere was rife with rumors and speculation that Pfizer would be laying off additional R&D personnel in December. However, it seems that the layoffs have been postponed and nobody at Pfizer seems to know when they will take place. Conventional wisdom suggests that job cuts will likely take place sometime after the holidays, probably in mid -January, 09.

Rod MacKenzie, Pfizer’s worldwide head of discovery research told reporters “Given the complexity of the changes within research, I have concluded that we will not be able to provide that clarity [for the layoffs] or communicate them by the end of the year." I suspect that he knows who will be getting pink slips but is reluctant to make the announcement until early next year because it would look awful if Pfizer lets people go right before the holiday season. 

Call me crazy, but I don’t think that publicizing lay offs (to be determined later) is good for employee productivity and morale. I have no doubt that rumors about the impending layoffs have been circulating at Pfizer for months. Unfortunately for Pfizer, one or more of its employees leaked the information and company executives are in damage control and spin modes. The inability of Pfizer executives to control internal information flow is just another example of why many industry analysts believe that Pfizer grew too quickly over the past decade. Nevertheless, hundreds and perhaps thousands of Pfizer employees will lose their jobs in the not so distant future.

Until next time…

Good Luck and Good Job Hunting (forget Groton, CT)

• Email This
• Print
• Comments
• Trackbacks (1)
• Share Link

Vincent Racaniello, my partner at BioCrowd, and I were chatting the other day about how cool it would be to develop a web-based map that was able to track infectious diseases outbreaks in real time. After a spirited chat, we both thought that we were on to something REALLY big. And, as is frequently the case, somebody else also had the very same idea.

For those infectious disease aficionados out there, you must check out the Health Map: A Global Disease Alert Map. The map was developed by Clark Freifeld and John Brownstein and is based on an algorithm that is beyond my comprehension. It is not as robust as the map that Vincent and I envisioned, but it is pretty cool and it works very nicely.

Until next time…

Good Luck and Good Disease Hunting!!!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

I know this is kind of odd, but I have recently begun to wonder which life sciences companies have layed off the most employees this past year. Well, for those of you out there who were also wondering we don't have to wonder any longer because Ed Silverman over at the Pharmalot blog has conveniently compiled a list of the top offenders for us. For those of you who may be wondering which company was number one on the list, it’s name begins with a “P” and ends with an “r.”

Until next time…

Good Luck and Good Job Hunting!!!!!!!!
 

• Email This
• Print
• Comments
• Trackbacks
• Share Link

It seems that every day a new American industry asks the US government for a bailout because of impending financial exigency. That said, I was somewhat surprised to learn today that the biotechnology industry is planning to ask Congress for a bailout. The plan calls for Congress to temporarily changes tax laws to allow unprofitable biotech companies to get cash now, in exchange for tax credits that they would pledge not to take if they eventually become profitable. The companies that receive the cash would pledge that the money would be used ONLY for research and development activities. The reasoning behind the proposed government bailout is that the infused capital would allow struggling biotech companies to keep their current employees, stay in business and help to stimulate the US economy. It is not clear whether or not all biotechnology companies—publicly traded or privately held—would be eligible for the bailout package.

Currently, there are 327 publicly traded and roughly 1,000 privately held biotechnology companies in the US. A majority of these companies are not profitable and operate almost exclusively on institutional and private venture capital funds. According to the Biotechnology Industry Organization (BIO), 125 of 327 public companies currently have less than 6 months of cash on hand—nearly double the total last year. It is not surprising that the biotechnology industry like most other US industries is struggling and feeling the impact of recent financial meltdown—there simply isn’t enough liquidity in the system to keep all companies afloat. While I am not opposed in principle to government bailouts, there are several reasons why the proposed rescue plan for the biotechnology industry doesn’t sense to me.

First, unlike the automobile industry which employs millions of workers, the biotechnology industry only employs about 200,000 workers, many of whom have advanced degrees and possess specialized technical skills. And, studies show that during recessionary periods workers with specialized skills are more likely to find employment after losing a job than their unskilled counterparts. This suggest that it may be better for the American economy in the long run if the government bails out the auto industry before it even considers a bailout for biotech. Nevertheless, BIO is actively lobbying for a government bailout because it believes that a bailout will not only stimulate the American economy but also help to “preserve American innovation and competitiveness.” Of interest, the pharmaceutical industry which shed over 123,000 jobs in the last year or so is not asking for government assistance. As one Washington lobbyist aptly quipped after hearing about the proposed biotech bailout: saving “research-based companies that employ 30 people won’t necessarily stimulate the economy.”

Second, the biotechnology business is inherently a very risky one. The failure rate among biotech companies is roughly 90%. And, as many of you know, biotechnology companies are always started with venture capital from investors who are willing to invest in risky projects because of possible financially-lucrative returns. Because of this, biotechnology executives are generally beholden to their investors rather than their shareholders, stakeholders or employees. Unfortunately, important business decisions are frequently made at venture-backed biotech companies for financial reasons rather than scientific or medical ones. Further, many financially-challenged, biotechnology companies that would benefit from the bail out started up almost a decade ago when venture capital was abundant and IPOs were daily events. In retrospect, many of these companies shouldn’t have been started in the first place because their technology platforms were either inadequately vetted or their business models were fundamentally flawed. I believe that these financially troubled companies ought to be allowed to fail just like the technology companies that had to close down in the early 2000s after the Internet bubble finally burst.

Third, why should unprofitable companies without products or revenues be bailed out and rewarded for failure? As I posited in a previous post, a company really isn’t a business until it has a product, generates revenues and turns a profit (or at least break even). If a company cannot create a viable business after 5-10 years of capital investments then it wasn’t a good value proposition at the outset. Perhaps a better use of the proposed bailout money would be for the US government to create public funding vehicles for companies that have developed promising new drugs that already have proof of concept in humans and are ready for clinical testing.

Finally, over the past decade, the biotechnology industry has spent hundreds of millions of dollars lobbying against the reimportation of drugs from foreign companies and the development of so-called follow-on biologics (potentially cheaper versions of blockbuster biotechnology drugs that have lost patent protection). This decade-long lobbying effort was undertaken to preserve America’s biotechnology monopoly and to insure that biotech drug prices remain high. Maybe BIO and its member companies should have considered using some of those monies to help struggling biotechnology companies rather than using it to influence politicians for tax breaks and pork barrel legislative initiatives.

Lastly and perhaps most importantly, why should taxpayer dollars be used to bailout an industry that has actively opposed and steadfastly refused to provide ALL Americans with access to reasonably priced, potentially life-saving biotech drugs? Because the biotechnology industry isn’t fundamentally different than any other American industry, I believe that the Darwinian principle of “survival of the fittest ought” to be applied to it. Unless, of course, you work on Wall Street or in Detroit—but don’t get me started!

Until next time…

Good Luck and Good Job Hunting!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

At its annual business briefing, Merck’s CEO, Richard Clark, announced that the company is creating a new division called BioVentures that will develop and sell follow on biologics. Clark said that the reason for this surprising decision was based on “the arrival of the Obama administration and renewed enthusiasm on Capitol Hill for legislation that could create an easier path for generic biotech medicines.”

Merck’s new BioVentures division will be built around the humanized yeast manufacturing platform developed by Glycofi, a privately-held, company that Merck acquired two years ago. While most of big pharma and big biotech publicly lobbied against new legislation that would make follow-on biologics legal in the US, Merck was surprisingly low key on the subject (now, we know why).

I first learned about Glycofi’s technology platform shortly after the company was formed in the early 2000 and immediately recognized its implication for follow-on biologics manufacturers. I immediately contacted Glycofi’s CEO at the time to see whether or not they would hire me as a “follow-on biologics consultant.” Sadly, because cash was tight (as it always is at start ups) I didn’t get the gig but I did get to know Tillman Gerngross, one of the Glycofi’s founders and its Chief Scientific Officer. Tillman and I spent some down time together at many of the follow-on biologics conferences that I organized where he was an invited speaker.

I was glad (mostly for Tillman) when I learned that Merck was going to by Glycofi for $400 million in cash. That said, the acquisition didn’t make sense to me at the time because Merck didn’t have a biologics division (although it did have a successful vaccine division).  After today’s announcement, Merck’s decision to purchase Glycofi makes perfect scientific and financial sense to me. I wish I could have gotten a piece of Glycofi before Merck bought the company. Nevertheless, I take solace in the fact that I, like Merck’s executives, can recognize a winning technology when I see one!

Maybe Merck will turn itself around after all!

Until next time…

Good Luck and Good Job Hunting!!!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

Pfizer may announce new job cuts by the end of next month as the company tries to curb spending before cheaper generic versions of its top- selling drug Lipitor flood the market in 2010. The cuts will likely take place in sales and marketing—Pfizer has cut more than 14, 000 jobs since 2007. 

Aren’t you glad that you didn’t take me up on that land deal in Florida?

Until next time…

Good Luck and Hang On!!!!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Sometimes reality is stranger then fiction. The Pharmalot blog reported today that US Senator Sherrod Brown, an Ohio Democrat, is nominating several candidates for the post and one of them is Peter Rost, MD!

For those of you who may not know Dr. Rost, he is a former Pfizer marketing executive who blew the whistle on some alleged marketing and sales violations at the drug maker. His court case is working its way up the judicial ladder and Dr. Rost apparently has the upper hand so far.

Pfizer fired Dr. Rost “for cause” after a raucous, public skirmish that went on for almost 2 years. After he left Pfizer, he wrote a book, worked for the Huffington Post and started his own blog, which currently has a post about his candidacy for the FDA Commissioner job. 

I first met Peter when he was still at Pfizer and I was organizing a meeting on drug reimportation (he is an ardent supporter). He agreed to talk at the meeting but unfortunately the conference was canceled for one reason or another. I have no doubt that he has the medical credentials and business acumen to handle the job. The one thing that worries me is his penchant for self promotion—something that is not a desirable trait in  an FDA Commissioner.

Time will tell. Personally, I would like to see Dr David Kessler come back and run the agency—another whistleblower (at UCSF) who ran the agency from 1990-1997 and did an outstanding job. The way things are going at FDA these days maybe being a whistleblower ought to be one of the requirement for the job!

Until next time…

Good Luck and Good Job Hunting

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The Pharmalot blog reported today that Bristol-Myers Squibb will be laying off 5% of its workforce (~ 34 employees) by year’s end at its manufacturing facility near Syracuse, NY. And, Sanofi-Aventis announced that it will be giving pink slips to about 10% of its sales force —about 650 reps—before the end of the year.

To make matters worse, Merck released its annual revenue projections for 2009 today which suggest that its earnings and revenue will not meet Wall Street expectations. Merck recently “cleaned house” and eliminated thousands of scientific and mid-management jobs. The list of pharmaceutical companies that have downsized in 2008 includes Merck, BMS, GlaxoSmithKline, Novartis, Schering Plough, Boehringer Ingelheim, Wyeth and Sanofi-Aventis. I probably missed a few but who is counting?

Until next time….

Good Luck and Hold On to Your Job (if you can)

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Recently, I have come across posts on blogs and websites reporting on lay offs and cost-cutting measures that are taking place at some biotechnology companies. A good example of this is a post that appeared yesterday on the Fierce Biotech Web Site. The headline read: “New round of layoffs, cost-cutting at biotechs.”  I thought “OMG this can’t be happening—not the biotechnology industry too!”

However, I am happy to report that many  of my concerns were assuaged after I read the post and realized that the reported downsizing was taking place at small companies, most of which were on shaky ground before the recession even began. Some of the companies that were mentioned included: Titan Pharmaceuticals, Pressure BioSciences, Insite Vision, WuXi PharmaTech Cayman and Targeted Genetics—not exactly titans (pardon the wordplay) of the biotechnology industry. 

There is no question that the current economic downturn will hurt some biotechnology companies (mostly because debt financing is so difficult to secure these days). That said, I think that the biotech industry may struggle a bit over the next couple of years but it will survive because it is in much better financial shape than most other American industries. 

It is important to note that the downsizing and cost-cutting taking place at many pharmaceutical companies is based almost exclusively on projected lost revenues that may occur 2-5 years two years from now—when many blockbusters drugs begin to lose patent protection— not on immediate cash concerns (most pharma companies have plenty of cash on hand). Pharma companies began downsizing in earnest about two years ago because they realized that they had gotten too big and their empty pipelines could no longer justify employing large numbers of unproductive employees. In my opinion, the current economic downturn provided pharmaceutical companies with a good excuse to continue to lay off employees, slash costs and maintain their stock prices. 

Many of the companies mentioned in the Fierce Biotech post have been around for 5-10 years and haven’t been profitable since their inception. As a former business partner once said to me “You don’t really have a business unless you have a product to sell and are profitable.” I suspect that many of these so-called biotechnology “companies” will go out of business—not because of the recession—but because they were unable to develop financially-viable products or services.

 Until next time…  

 Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

This post was originally written by Vincent Racaniello, a long time friend and colleague, who runs the Virology Blog. 

Here is what Vincent had to say:

My colleagues (generally the older ones) often ask me why I blog or podcast. They believe that I am wasting my time. After all, I am a scientist, and it is my job to carry out research. In order to do this I must publish papers and obtain grants. The grant funds are used to pay salaries (mine and those in my laboratory) and purchase the supplies needed for research. In my institution, nothing matters except raising money for research. Teaching, mentoring, and other community services mean very little. Blogging and podcasting do nothing to help fund my laboratory.

Here are my answers. Why did I go into science? Because my parents (physician and teacher) and my teachers inspired me. But for many other children, the only inspiration they have is their teachers. They need input from other sources. I believe I can help provide that input over the internet.

Most people - kids, teens, adults - don’t understand science. Their teachers can provide only a very rudimentary, often flawed view of some of the fundamental concepts. While I cannot cover all of science, I can do a good job of teaching what I know. I have been studying and thinking about viruses for over 30 years, so I understand them quite well. I am also able to talk and write about them clearly and concisely, a gift I probably received in part from my teacher parent. These qualities put me in a unique position to educate the public about viruses. 

Early in my career, I didn’t think much about teaching. I focused on research. Later I realized I had a reasonable ability to communicate what I knew, which turned into a love of teaching. My blogging and podcasting about viruses represent part of the effort to impart some of my knowledge to the public. 

As I have read and heard many times on the web, if you want to blog or podcast, do it about something you are passionate about. And that is what I am doing.

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Vincent Racaniello, Professor of Microbiology at the College of Physicians and Surgeons at Columbia University and co-founder of BioCrowd ,has created a weekly series called This Week In Virology (TWiV). Each week Professors  Racaniello and Dickson Despommier (another Columbia virologist) discuss the latest developments and public health concerns for a variety of viral diseases.

The weekly discussions are packaged as podcasts, posted on TWiV and Science Podcasters.org and can be downloaded from iTunes. Dr. Racaniello eventually wants to offer TWiV in a vcast format and use it to inform the public and teach students about viral diseases.

So far, Vincent and Dick have created nine TWIV podcasts. Some of viruses that they have discussed include: HIV, Polio, Lassa fever, Rabies, West Nile Virus and even video game viruses. The podcasts are interesting, informative and a good way to learn something about virology—something that may liven up your daily commute!

Until next time,

Good Luck and Good Job Hunting

• Email This
• Print
• Comments
• Trackbacks
• Share Link

We in America have grown accustomed to the constant barrage of direct-to-consumer (DTC) advertising of prescription drugs provided to us daily by pharmaceutical and biotechnology companies. That said, some of you may be surprised to learn that DTC advertising of prescription drugs is only permitted in two countries in the world: New Zealand and the US.

According to William Burns, an executive at Roche Pharmaceuticals, “Direct-to-consumer promotion was the single worst decision for the industry." He added, "When industry says we're spending all the money on R&D but actually it's spending it on TV advertising to preserve margins, it doesn't get much credibility." It may not provide much credibility to the industry but is sure does help sales.  reported that a total of $4.2 billion was spent on DTC drug ads in the U.S. in 2005, up 330 percent from 1996.

Apparently Mr. Burns is not alone in his opinion. Angus Russell, chief executive of Britain's Shire Pharmaceuticals also condemned DTC.  As many of you know, I ‘m not a big fan of DTC nor am I flag-waving American but I find it rather curious that after almost 12 years of DTC advertising that European pharma executives are suddenly speaking out against the practice. Could this be little more than a ploy to get the European Commission to re-examine and possibly loosen it restrictions on the way prescription drugs are promoted in the EU? Quite coincidentally, the European Commission is in the process of drawing up legislation that would allow a degree of information to be disseminated about medicines by their makers, although advertising pharmaceuticals would remain banned. The legislation was initially expected to be unveiled by the European Union's executive arm last week but has been delayed.

Drug makers have long campaigned against rules that prevent them from talking directly to consumers in Europe, despite a wealth of often unreliable information being available on the Internet. I think this statement by Mr. Burns sums up the situation "You've got the two extremes on the planet, where we (drug makers) are given access to the public in America, which is too much, and in Europe we're not given access to information" (sounds like sour grapes to me).

Maybe a compromise between the two extremes would be a solution acceptable to both American and European regulators? 

Until next time…

Good Luck and Good Job Hunting!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Late yesterday, drug maker and consumer healthcare giant Johnson and Johnson announced that it was buying Mentor, a Santa Barbara, CA maker of skin care products, liposuction equipment and MemoryGel breast implants. According to industry analyst the $1.07 billion that J&J will spend to purchase the company “represents a giant premium for Mentor.” Mentor will become a stand-alone unit of J&J’s Ethicon a leading supplier of sutures, mesh and other surgical products. The cosmetic surgery and anti-aging markets are huge and are expected t to grow as the baby boomer generation continues to age.

J&J is on something of a buying spree and will continue to buy specialty companies to to offset possible losses that may from a weak drug pipeline of its pharmaceutical division. In November, the company purchased Omrix for $438 million, a biopharmaceutical that develops biosurgical and passive immunity products. The deal is expected to close this month.

Unlike most other pharmaceutical companies, J&J has been able to successfully run a diversified conglomerate company that specializes in both pharmaceutical and consumer healthcare products. It is a cash rich company that has a reputation for treating its employees very well! Who said that “beauty is only skin deep?”

Until next time

Good Luck and Good Job Hunting!!!!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

According to a recent report from the consulting firm Ernst and Young, cost cutting and downsizing are no longer the primary objectives for most pharmaceutical companies. Instead, they are mulling over the new challenges that universal health care may bring and how to better reach consumers in emerging markets. 

In a recent interview, Carolyn Buck Luce, one of the paper’s co-authors said “in our previous report, cost containment was one of the most important initiatives. In this report we found more of a balanced approach where optimizing cost was [just] one the many objectives. Only 40 percent of the executives said optimizing costs was their most important initiative, compared to a similar study in 2007 where 92 percent of those surveyed ranked cost reduction as their main initiative. In the latest survey, 66 percent of executives said the most important strategic initiative was reinvigorating the R&D pipeline, while 40 percent said expanding into new markets and restructuring their marketing and sales programs to become more customer-centric were their main areas of focus. “

One of the most telling quotes in the piece is: “There was an awful lot of focus on costs a year ago, when companies realized there was a lot of fat in their companies and a lot of opportunity to cut costs.” Does that mean that pharma really didn’t have to lay off tens of thousands of employees over the past year? It kind of makes you wonder doesn’t it? And, if you believe that pharma is truly finished with downsizing--would you be interested in a great deal on some land in Florida?

Until next time…

Good Luck and Try to Hang On to Your Job!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link